Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: Subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 679-687

  Mease, Philip J ^a   Clauw, Daniel J ^b   Trugman, Joel M ^c   Hpalmer, Robert ^c   Wang, Yong ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Fibromyalgia; Post hoc analysis; Responders; Symptoms

Indexed keywords

MILNACIPRAN; PLACEBO;

ADULT; ANALGESIA; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; PAIN THRESHOLD; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VISUAL ANALOG SCALE;

EID: 84912122737     PISSN: 11787090     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S70200     Document Type: Article

References (24)

1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19–28.
2. Vincent A, Lahr BD, Wolfe F, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013;65(5):786–792.
3. Gendreau R., Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32(10):1975–1985.
4. Mease PJ, Clauw DJ, Gendreau R., et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(2):398–409.
5. Clauw DJ, Mease P, Palmer RH, Gendreau R., Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30(11):1988–2004.
6. Arnold LM, Gendreau R., Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(9):2745–2756.
7. Trugman JM, Palmer RH, Ma Y. Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study. Curr Med Res Opin. 2014;30(4):589–597.
8. Goldenberg DL, Clauw DJ, Palmer RH, et al. Durability of therapeutic response to milnacipran for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med. 2010;11(2):180–194.
9. Ferrera R, Palmer R, Wang Y, Gendreau R. Improvements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: results from 2 double-blind, dose-controlled extension studies [abstract]. J Pain. 2009;10(4 Suppl 1):S60.
10. Arnold LM, Palmer RH, Ma Y. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clin J Pain. 2013;29(12):1021–1028.
11. Clauw DJ, Mease PJ, Palmer RH, Trugman JM, Wang Y. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Res Ther. 2013;15(4):R88.
12. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419–431.
13. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–158.
14. Mease PJ, Clauw DJ, Christensen R, et al. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol. 2011;38(7):1487–1495.
15. Arnold LM, Williams DA, Hudson JI, et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum. 2012;64(3):885–894.
16. Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain. 2011;27(3):185–193.
17. Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012;153(10): 2073–2082.
18. Raskin P, Huffman C, Toth C, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain. 2014;30(5):379–390.
19. Savella (milnacipran HCl) [prescribing information]. St Louis, MO: Forest Pharmaceuticals, Inc.; 2013.
20. Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties [Erratum, Arthritis Res Ther 2009;11:415]. Arthritis Res Ther. 2009;11(4):R120.
21. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.
22. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
23. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114(7):537–545.
24. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18(5): 728–733.